Impact of etanercept co-therapy with Methotrexate and prednisone in Canadian patients with immune-mediated inflammatory diseases (IMIDs)

Trial Profile

Impact of etanercept co-therapy with Methotrexate and prednisone in Canadian patients with immune-mediated inflammatory diseases (IMIDs)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate; Prednisone
  • Indications Ankylosing spondylitis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top